Bioprogress is a stock I have been in and out of quite a few times since it floated in May but not much mention here on the Investors' Room. Does anyone else follow this stock. I see it is up 1.5p today and a few good buyers seem to have appeared.

Yeah, right. ;-))

:-)

Just for the mafiosa, Dil and Big AL


May help the price a little. At least profit looks on its way.


Home Log Out Upgrade Our Services My Account Contact Help



Stockwatch Level 2 Portfolio Charts Shares Magazine Research Quote Indices Market Scan Company Zone Traders' Room
NewsWatch Trades Terminal Alerts Stock Screener Heatmaps News Mobile Futures CompanyAV Investors' Room
World Markets Webcast Directory Bookshop Personal Finance Mortgages Forex Loans Credit Cards Simply Chart ISAs








BioProgress PLC
06 June 2007


For Immediate Release 6 June 2007



BioProgress launch first SoluleavesTM products in UK



London, UK, 5th June 2007: BioProgress plc ('BioProgress' or the 'Company')
(AIM: BPRG; NASDAQ: BPRG), the specialty pharmaceutical and healthcare company,
is pleased to announce the launch in the UK of the first of its range of
SoluleavesTM, melt in the mouth products.



The first two SoluleavesTM products to be marketed will be, Caffeine Soluleaves
TM - energy boost, and Zinc and Echinacea, which helps boost natural defences
against colds and flu. Other SoluleavesTM products including Vitamin B complex
and anti-snoring will be launched in the coming weeks.



The SoluleavesTM range of products will be marketed through the newly acquired
PharmaHerb Limited, a specialist Over The Counter (OTC) products company, using
the Kudos brand. Distribution will be through its established niche health
shops, pharmacies, supermarket chains, as well as its direct to consumer
internet selling (
www.kudosvitamins.com
).



The market for energy products in the UK is valued around 700m, with the UK
cough cold market valued at 430m. The company believes the products possess a
number of advantages over existing market products such as being quick to
disperse in the mouth leading to rapid onset of action, and suitable for people
who have difficulty swallowing tablets and capsules. Peak sales are estimated to
be within 1 to 1.5% of their appropriate market.



Richard Trevillion, Chief Executive Officer, of BioProgress commented:

'It is testament to the strength and depth of the Company's infrastructure that
BioProgress has been able to reformulate to UK standards and launch new products
in record time. This launch has been timed to capitalize upon the recent
acquisition of PharmaHerb. It will also be the first time consumers will have
access to the benefits of the SoluleavesTM system in the UK market'.











For further information:


BioProgress Plc + 44 (0) 20 7098 9881
Richard Trevillion, CEO
Steve Martin, CDO
Hiral Patel, CFO

Buchanan Communications + 44 (0) 20 7466 5000
Rebecca Skye Dietrich
Mark Court





About BioProgress

BioProgress plc is an innovative specialty pharmaceutical and healthcare
business based around its platform technologies in polymer and film systems.
Listed on London's AIM in May 2003 and on US NASDAQ in October 2004, the company
has over 80 patents granted or in application within 24 patent families and has
product development agreements and strategic alliances with several global
companies. As a virtually integrated business, BioProgress has acquired sales
and marketing resources within Europe and the US as a launch mechanism for its
own pharmaceutical products. The business continues to develop innovative
delivery mechanisms using its XGELTM polymer technology, replacing the need to
use animal-derived gelatine in pharmaceutical and healthcare products. For
further information please go to
www.bioprogress.com




Forward-Looking Information.

The Ordinary Shares of BioProgress plc are registered under the US Securities
and Exchange Act of 1934. To the extent that this announcement contains certain
'forward-looking statements' within the meaning of the Private Securities
Litigation Reform Act of 1995, this paragraph applies. These statements are
based on management's current expectations and are subject to uncertainty and
changes in circumstances. Actual results may vary materially from the
expectations contained in the forward-looking statements. The forward-looking
statements in this release include statements addressing future financial and
operating results and the timing and benefits of the reorganisation. Detailed
information about factors pertinent to the business of the company that could
cause actual results to differ is set forth in the Company's filings with the
Securities and Exchange Commission. The Company is under no obligation to (and
expressly disclaim any such obligation to) update or alter its forward-looking
statements whether as a result of new information, future events or otherwise.
This announcement is for information only and does not constitute an offer or
invitation to acquire or dispose of any securities or investment advice. The
distribution of the announcement and/or issue of securities in certain
jurisdictions may be restricted by law. Persons into whose possession this
announcement comes are required to inform themselves about and to observe such
restrictions.












This information is provided by RNS
The company news service from the London Stock Exchange





| Register | Our Services | About MoneyAM | Terms and Conditions | Privacy Policy | Investment Warning | Content Standards | Corporate Solutions | Advertise With Us |
2006 MoneyAM

And another. why can't SEO do the same.


News Article
News Flash: SlimThru Update
06/06/2007


BioProgress and Melbrosin have been working together on the television support of the unique food and weight management brand, SlimThru which has achieved excellent results.



The UK TV campaign breaking across terrestrial and satellite channels throughout June 2007 for a period of six weeks forms part of a wider marketing campaign including a radio campaign, press promotions and PR. This directs people to the www.slimthru.co.uk website which achieved a record of almost 10,123 contacts in the first 5 days of advertising.



SlimThru has been successfully launched in a number of EU countries under various related brand names and has achieved market leadership in Austria in the first 5 weeks of marketing. Similar successes are being achieved in other markets.



BioProgress PLC will continue to work as co-promotion partner with Melbrosin using its developing network of retail outlets and supporting the media campaign.

Not much of a reaction there. I'm still surprised all this good news has no effect whatsoever.

Shame for holders I guess.

I have a feeling more and more are realising that the smaller companies with large R and D costs, promises for tomorrow, with little cash flow have a disproportionate risk. Also in BPRG share price has been a heltershelter ride for years.

Another factor is sentiment to the market at the moment, my guess for the last few days the flow of cash was out of the market in general. The same information in a more bullish market would have lifted it.

BPRG promises profit for this year, a change and future projections are promising. The market they are catering for is substantial and sustainable.
I would consider it a good defensive stock.
I think the outlook is good. But DYOH.

If you are holding still this may cheer your hearts.



Also worth a look at projected earnings.



It is up 7.1% on last nights close.


I think this is one for the future, but check its PE against your toleration.

I have held on and off for years.



News Article

AGM Statement and Company Update
19/06/2007

BioProgress plc ('BioProgress' or the 'Company')

AGM Statement and Company Update

London, UK, 19 June 2007: BioProgress (AIM: BPRG), the speciality pharma and healthcare company, is holding its AGM at 2.30pm today and will make the following update.

Trading

The Company is pleased to announce that it is trading above annualised turnover expectations for the half year to June 2007. Its current sales and marketing operations, are performing to expectations and benefiting from increased market awareness due to several recent product launches. With the product portfolio currently focused upon seasonal products with peak sales expected from September and with the additional acquisition of Rocgel, BioProgress is confident that the progress made through the first half of the year will be maintained through the second half of the year.

Partners

BioProgress is also pleased to announce a new commercial relationship with Merck-Serono, one of the largest pharmaceutical companies in the world. The Company is partnering four of its developed and commercialised technologies with a division of Merck-Serono, comprising TabWrap, FastWrap, SoluPoland Meltums for products specifically in the area of female healthcare, a global $54 billion market. The Company is also working with an additional three global pharmaceutical companies all with multiple enabling systems. In addition, the Company is currently in detailed product and technology discussions with over 15 different pharmaceutical companies for commercial partnering arrangements. The technology focus of these developments are related to the TabWrap, FastWrap, Soluleaves and SoluPol enabling systems. The product indications are focussed within the analgesic, cough/cold and gastro-intestinal categories. The developments with partners include the use of the technology with category leading brands within the US and other markets.

BioProgress will receive milestone, royalty and licensing payments along with development and co-commercialisation rights. Some of the partner programs incorporate profit-sharing agreements. The Company is expecting an increase in the number of new partner development programs during the second half of 2007. The Company will also maintain manufacturing rights for certain of these arrangements.

The Global OTC analgesic market is worth $6.2 billion in 2007 (Datamonitor) with the US, UK and Japan being the largest three single national markets. This market centres around paracetamol/acetaminophen, ibuprofen and aspirin as the major molecules. The global OTC cough/cold market is worth $10.5 billion with the USA, Japan and Germany being the three largest national markets.

In addition, the Company has identified its preferred partner for its smoking cessation product, DBP121. The marketing aspects of the partnering program are currently being assessed on a global basis with BioProgress retaining certain rights to some territories and the manufacturing rights. The global market size is $2.1 billion within the OTC arena with the US having an additional $300m for prescription only products.

Products

BioProgress is also pleased to announce that it is launching a new topical treatment for the treatment of cellulite. Using natural remedies and caffeine, the hypoallergenic gel uses BioProgress' patented technology to act as drug penetration enhancer for molecules across the skin. The market is significant with over 10% of all women in France using a topical treatment for cellulite and body toning.

The product has been shown to deliver the active ingredients over twice as effectively as the leading brand products. The topical treatment will be marketed as Kudos Anti-cellulite Cream and will form an integral marketing strategy with the Slimthru brand. The Company"s co-promotion partner, Melbrosin International, will be launching the product within the Austrian and German markets. The anti-cellulite creams market is worth more than $30m in the UK alone. The global cosmetics market was valued by Euromonitor at $253.6bn in 2005, up 8.2% on 2004. The technology has a number of other advantages and is currently being investigated for the area of burns associated with radiotherapy.

Technologies

In parallel with the above significant and exciting developments, the Company is pleased to announce that its TabWrap enabling system, together with its derivatives EntWrap and FastWrap, are now in commercial scale-up and validation. The final system, housed in a fully compliant CGMP facility, will be shown at the AGM.

The Company is also pleased to announce the successful development of a new generation of XGEL films for the TabWrap machine. The new generation film is able to be manufactured at a far higher rate than previously possible enabling the TabWrap system to be run at higher operating speeds. This has resulted in a significant decrease in the operating costs of the TabWrap system making it more competitive within the marketplace.

Richard Trevillion, Chief Executive Officer, BioProgress said:

"It has been a very exciting and productive year for the Company. The relationship with Merck-Serono announced today is further validation and a fantastic endorsement of BioProgresss valuable technology. BioProgress has come a long way from concept to fully validated commercial products that earn revenue. The dedicated team at BioProgress has worked extremely hard and can be proud of its achievements and we look forward to a highly successful year ahead and the further enhancement of shareholder value.

Steve Martin, Chief Development Officer, BioProgress, said:

We are working with more partners than we ever have done in the past across a range of technologies. Along with our own product development program, we will see a number of innovative product launches including some significant partner brands.

For further information:



BioProgress Plc
+ 44 (0) 20 7098 9881

Richard Trevillion, CEO

Steve Martin, CDO

Hiral Patel, CFO





Buchanan Communications
+ 44 (0) 20 7466 5000

Rebecca Skye Dietrich

Mark Court



About BioProgress

BioProgress plc is an innovative specialty pharmaceutical and healthcare business based around its platform technologies in polymer and film systems. Listed on London's AIM in May 2003 and on US NASDAQ in October 2004, the company has over 80 patents granted or in application within 24 patent families and has product development agreements and strategic alliances with several global companies. As a virtually integrated business, BioProgress has acquired sales and marketing resources within Europe and the US as a launch mechanism for its own pharmaceutical products. The business continues to develop innovative delivery mechanisms using its XGEL polymer technology, replacing the need to use animal-derived gelatine in pharmaceutical and healthcare products. For further information please go to www.bioprogress.com

Forward-Looking Information.

The Ordinary Shares of BioProgress plc are registered under the US Securities and Exchange Act of 1934. To the extent that this announcement contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, this paragraph applies. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may vary materially from the expectations contained in the forward-looking statements. The forward-looking statements in this release include statements addressing future financial and operating results and the timing and benefits of the reorganisation. Detailed information about factors pertinent to the business of the company that could cause actual results to differ is set forth in the Companys filings with the Securities and Exchange Commission. The Company is under no obligation to (and expressly disclaim any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events or otherwise. This announcement is for information only and does not constitute an offer or invitation to acquire or dispose of any securities or investment advice. The distribution of the announcement and/or issue of securities in certain jurisdictions may be restricted by law. Persons into whose possession this announcement comes are required to inform themselves about and to observe such restrictions.

BioProgress says trading above annualised turnover expectations in H1
AFX


LONDON (Thomson Financial) - Speciality drug company BioProgress PLC said it is trading above annualised turnover expectations for the half year to June 2007 and that it is confident of maintaining its first-half progress through the second half.

BioProgress said it has struck a commercial relationship with Merck Serono for female healthcare products and that it is in detailed product and technology discussions with over 15 different pharmaceutical companies for commercial partnering arrangements.

Additionally, the company said it has identified its preferred partner for its quitting smoking product, DBP121. It is assessing the marketing aspects of the partnering programme on a global basis, with BioProgress retaining certain rights to some territories and the manufacturing rights.

BioProgress added that it is launching a new topical treatment for cellulite and said that it looks forward to a highly successful year.

TFN.newsdesk@thomson.com

Can't see the magic word "profit". It's all a bit turnover-ish, Fred. ;-))

BA,Agreed but for still a young company it is taking the right steps and projected figures 12/07 "hopes" shows profit out of rising double turnover. These figures base on reports before information to-day.

DYOH, but I am holding quite a few and will do so for the longterm.

Fred - no doubt they're getting there. Happy to watch here ................ and occasionally take the mickey! ;-)))

In my opinion, for what's worth...now is the time to buy BPRG....I've never been in it before but things look promising to me and I think that BPRG may well make me lots of profit...hopefully like SEO (l (6 x my money and I stayed out of the bad bit) but BPRG is round the other way...ie; they've had their bad bit and now the good times are gonna roll.
All IMHO dyor etc
Di
:-)

For anyone who may be interested there is a Web TV chat at 12.30 today as part of BPRG's ongoing advertising campaign for Slimthru. You can get the details from:-
http://www.bioprogress.com/media/index.php

Di!!! Howdy. Hmm, BPRG, eh? It's got to do well some time. The question is when.

;-)

Hi Al...nothing has to do well although I have a feeling BPRG will!!! Talking of shares which are doing well. Do you still hold AIMR?

Blimey - AIMR? Can't even remember when I held them.

Just looked at chart. Wish I still had them ;-)) Luckily I'm having a good week with CPH and a good month of two with RDSB and HAMP - bottom fished oerfectly for a change. LOL

Best of luck with your BPRG.

Al...I'm glad you are doing well with your shares....I remember you saying you bought AIMR as a 'do or die share' around the time I bought them....you would have doubled your money if you had kept them...never mind hopefully other shares have been as good to you.
I buy everything on 'gut feel' and it seems to be a do or die portfolio where most live, a few have 9 lives and the odd one dies...it works for me big time but I wouldn't recommend it to anyone else!!!
Di
:-)

Dyamite, are you teasing BA.

Watch BPRG for after the bell B/S for a few days.

Might be interesting.

me tease?? Never

;-))

Fred - I have met the lovely Di.